Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This study is measuring blood markers like high-sensitivity troponin I, NT-proBNP, and ST2 to predict heart-related outcomes in people with type 2 diabetes — would getting these markers tested as part of my regular care give me useful information about my cardiovascular risk?
2. 2Since this trial is observational and no longer enrolling, it's focused on tracking outcomes like all-cause mortality rather than testing a new treatment — does this mean my doctor could use findings from this kind of research to guide decisions about monitoring my heart health?
3. 3The study is looking at three specific biomarkers together — are any of these already available as standard tests my care team could order, and would my results be meaningful without the full research context this study provides?
4. 4Given that I have type 2 diabetes and may be at risk for cardiovascular complications, are there currently approved strategies or treatments my doctor recommends based on similar biomarker evidence, rather than waiting for results from studies like this one?
5. 5Since this trial is still active but not enrolling new participants, is there a comparable study or registry that I could discuss with my doctor that might let me contribute to this kind of cardiovascular risk research while also getting closer monitoring?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.